Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA Prepares For More TRIPS Import Talks; U.S. Lays Out “Interim Plan”

Executive Summary

The Pharmaceutical Research & Manufacturers of America expects TRIPS negotiations on the importation of drugs made under compulsory license to resume within several weeks

You may also be interested in...



WTO Rx Compulsory Licensing Agreement Solves “Symbolic” Issue, USTR Says

World Trade Organization final agreement on drug compulsory licensing represents progress on a "symbolic" issue, Assistant U.S. Trade Representative for Services, Investment and Intellectual Property James Mendenhall said Sept. 2 at an American Enterprise Institute forum on the Trade-Related Aspects of Intellectual Property Rights agreement

WTO Rx Compulsory Licensing Agreement Solves “Symbolic” Issue, USTR Says

World Trade Organization final agreement on drug compulsory licensing represents progress on a "symbolic" issue, Assistant U.S. Trade Representative for Services, Investment and Intellectual Property James Mendenhall said Sept. 2 at an American Enterprise Institute forum on the Trade-Related Aspects of Intellectual Property Rights agreement

Pfizer CEO Sees “Emerging Consensus” On Global Patent Protection Issues

There is an "emerging consensus" that the best approach to providing antiretroviral drug therapies to developing countries includes strong intellectual property rules, which then make product donations possible, Pfizer CEO Hank McKinnell, PhD, said

Related Content

UsernamePublicRestriction

Register

PS041061

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel